Methocarbamol Shortage: What Providers and Prescribers Need to Know in 2026

Providers are increasingly hearing from patients who can't fill their Methocarbamol prescriptions — and the reasons extend beyond a simple supply-and-demand mismatch. This briefing summarizes the current availability landscape, the structural factors driving disruptions, clinical prescribing considerations, therapeutic alternatives, and practical tools to help your patients access their medications.

Current Supply Status: What the Data Shows

Methocarbamol is not currently listed as a formal national drug shortage by the FDA or ASHP. However, the ASHP shortage database documents a significant contraction in the number of manufacturers supplying the drug:

Par Pharmaceuticals: Discontinued methocarbamol tablets in July 2018

Virtus Pharmaceuticals: Discontinued in June 2019

Endo Pharmaceuticals (Robaxin brand): Discontinued January 2020

Solco Pharmaceuticals: Active ingredient shortage (timing variable)

Hikma: Not actively marketing methocarbamol tablets

Currently active suppliers include Bayshore Pharmaceuticals, Camber Pharmaceuticals, and Granules Pharmaceuticals. This narrow supplier base — serving approximately 5 million annual prescriptions in the U.S. — creates structural fragility that translates into localized pharmacy-level shortages even absent a formal national designation.

Prescribing Considerations in the Current Environment

Given the supply environment, providers can take several steps to minimize the impact on patients:

Prescribe strength flexibility: When clinically appropriate, note on the prescription that either 500 mg or 750 mg is acceptable with appropriate dosage adjustment. This gives the pharmacist the flexibility to substitute the available strength.

Confirm availability before writing: In areas with known supply issues, a quick check of local pharmacy availability before sending the prescription can save your patient unnecessary trips and delays.

Counsel patients on independent pharmacies: Independent pharmacies often use different distributors than major chains and are more likely to have stock when chains don't.

Special Populations: Who Needs Extra Attention

Several patient populations require special consideration when prescribing methocarbamol or selecting alternatives:

Elderly patients (65+): Methocarbamol appears on the AGS Beers Criteria as potentially inappropriate for older adults due to CNS depression risk and fall potential. If the drug is unavailable and the patient requires a muscle relaxant, consider a reduced dose with close monitoring, or prioritize non-pharmacological approaches.

Myasthenia gravis patients: Methocarbamol may inhibit the effect of anticholinesterase agents like pyridostigmine. Use with caution and monitor neuromuscular function.

Epilepsy patients: IV administration of methocarbamol has been associated with seizure onset in epileptic patients. Avoid IV form in this population.

Renal impairment: The IV formulation contains polyethylene glycol 300 and is contraindicated in patients with known or suspected renal pathology. The oral formulation can be used with monitoring.

Hepatic impairment: Methocarbamol clearance is reduced approximately 70% in patients with cirrhosis (mean half-life increases to ~3.4 hours versus ~1.1 hours in healthy subjects). Dose reduction and monitoring are warranted.

Therapeutic Alternatives: Clinical Comparison

If Methocarbamol is unavailable, the following alternatives are clinically appropriate for most acute musculoskeletal indications:

Cyclobenzaprine (5-10 mg TID): Most evidence-supported option for acute musculoskeletal pain. Avoid in patients with arrhythmias, heart block, hyperthyroidism, or on MAOIs. Watch for serotonin syndrome risk with SSRIs/SNRIs. Avoid in patients 65+.

Tizanidine (2-4 mg TID): Alpha-2 agonist; shorter duration of action. Contraindicated with ciprofloxacin and fluvoxamine. Monitor LFTs, blood pressure. Useful for both spasm and spasticity.

Baclofen (5-10 mg TID, titrate): GABA-B agonist; best for neurological spasticity (MS, SCI, CP). Must taper — abrupt discontinuation can cause severe withdrawal including seizures.

Metaxalone (800 mg TID-QID): Least sedating option. Monitor LFTs. Higher cost may be a barrier for uninsured or underinsured patients.

Drug Interactions: Key Points for Prescribers

Methocarbamol's primary drug interactions are pharmacodynamic (CNS depression). Key interactions include:

Opioids and other CNS depressants: additive sedation/respiratory depression risk

Alcohol: enhanced CNS depression

Pyridostigmine: methocarbamol may reduce efficacy; caution in myasthenia gravis

Lab tests: may cause false-positive interference with 5-HIAA and VMA urine screening tests — inform labs accordingly

How to Help Your Patients Find Methocarbamol

Direct your patients to medfinder.com — a service that contacts pharmacies near the patient's ZIP code to identify which ones have Methocarbamol in stock and can fill the prescription. Results are texted directly to the patient. This eliminates the need for patients to make multiple phone calls and allows them to get their medication faster.

For a detailed provider resource, see our guide: How to Help Your Patients Find Methocarbamol In Stock.